注射用纤溶酶联合阿司匹林治疗脑梗死的临床疗效

The clinical efficacy of fibrinolytic enzymes combined with aspirin for cerebral infarction disease

目的观察注射用纤溶酶与阿司匹林(乙酰水杨酸)联合治疗脑梗死的临床效果。方法对福建晋江市医院2011年1月—2012年12月收治的160例脑梗死患者(均发病后6 h以上入院,不适合静脉溶栓)随机分为2组。治疗组静脉滴注纤溶酶200 U加100 mg阿司匹林口服1次/d,对照组仅口服相同剂量的阿司匹林,两组均常规口服20 mg阿托伐他汀1次/d,共治疗2周。比较治疗前后血液流变学指标变化,以及治疗1个月、6个月后的预后。结果治疗组肢体瘫痪较对照组明显好转,效果明显优于对照组,无明显病情加重病例。结论注射用纤溶酶与阿司匹林联合治疗脑梗死,安全有效,值得推广应用。

Objective To observe the effect of injectable fibrinolysin and Aspirin （acetylsalicylic acid） in treatment of cerebral infarction. Methods Patients with cerebral infarction （160 cases） presenting more than 6 h after symptom onset from January 201t to December 2012 admitted to Jinjiang Municipal Hospital were randomly divided into treatment group （injectable fibrinolysin iv ggt 200 U and acetylsalicylic acid po 100 mg） and control group （Aspirin po 100 mg）. The patients in both groups were treated with atorvastatin （20 mg/d ） for 2 weeks. Results The patients in the treating group had better paralysis recovery than those in the control group. Conclusion The therapy of injectable fibrinolysin and Aspirin is effective and safe.